In order to improve user experience, ORYX GmbH & Co. KG uses cookies. By continuing to browse this website, you agree to our use of cookies. For further information, please see our Privacy statement.
Accept

Translational Medicine
taking innovation from lab to patient

PLEASE NOTE:

This website is currently under complete revision, also to demonstrate new positive clinical data (November 2022).

 

ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Nordwest Hospital Frankfurt, Darmstadt Clinic and leading experts as well as an outstanding network of scientific and clinical advisors.

Oncolytic Virus

Oncolytic viruses infect and lyse tumor cells and evoke a strong anti-tumor immune response. ORYX develops the oncolytic parvovirus H1 (H-1PV) which is a wild type rat virus with effects in a broad range of human tumors. Clinical development began in 2011 and continues to show promising results in terms of safety, efficacy and immune response.

Parvovirus H1
Source: DKFZ

Therapeutic Vaccines

Therapeutic vaccines treat cancers by enhancing a patient’s natural defenses against the tumor. ORYX on the one hand focusses on the human cyclin-dependent kinase inhibitor p16, a tumor antigen expressed in various cancers. On the other hand, ORYX focusses on MSI, which targets cancers that arise from the lack of DNA mismatch repair.

p16 MSI

News:


11.11.2019: ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

04.11.2019: ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

30.10.2019: ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

16.05.2018: ORYX to Present Positive Clinical Data for Oncolytic Virus ParvOryx in Combination with Immune Modulators at CIMT Annual Meeting 2018